AnaptysBio Inc Stock
Price
Target price
€52.62
€52.62
-1.130%
-0.6
-1.130%
€67.94
15.05.26 / Frankfurt
WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
AnaptysBio Inc Stock
We can see a decrease in the price for AnaptysBio Inc. Compared to yesterday it has lost -€0.600 (-1.130%).
With 27 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 67 € shows a positive potential of 27.33% compared to the current price of 52.62 € for AnaptysBio Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for AnaptysBio Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | -1.130% | -10.358% | -8.391% | 190.718% | 22.372% | 197.288% | 145.888% |
| NanoViricides Inc. | -2.670% | 14.063% | 52.880% | 28.070% | 56.989% | 40.385% | -45.644% |
| Ocuphire Pharma Inc. | -2.260% | -5.263% | -8.085% | 406.448% | 156.837% | -22.995% | - |
| Actinium Pharmaceuticals Inc. | -1.090% | 4.340% | 16.913% | -15.701% | -8.368% | -85.729% | -81.094% |
Comments
AnaptysBio (ANAB) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market sale of 3,900 shares for a transaction value of $193,342.50, representing 28.82% of his direct holdings
What Investors Should Know About a $163K AnaptysBio Insider Sale
Paul F. Lizzul, the chief medical officer of AnaptysBio (NASDAQ:ANAB), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as